Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873037 · ClinicalTrials.gov registry record · NA
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
A NA study of Overactive Bladder and Overactive Bladder Syndrome, sponsored by Corewell Health East.
- Recruiting
- Registry status
- NA
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT04873037: Recruiting NA study of Overactive Bladder and Overactive Bladder Syndrome, sponsored by Corewell Health East.
NCT04873037 is a NA study of Overactive Bladder and Overactive Bladder Syndrome that is actively recruiting participants, run by Corewell Health East. The registered enrollment target is 166 participants, below the 204-participant average among 46 other Overactive Bladder trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04873037, a NA study of Overactive Bladder and Overactive Bladder Syndrome, is actively recruiting participants, sponsored by Corewell Health East.
- RECRUITING
- Registry status
- NA
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to compare the Emsella Chair therapy to Sham and to determine whether electromagnetic technology is effective in the treatment of overactive bladder (OAB). Currently there are no other studies utilizing the Emsella Chair for the treatment of OAB. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.
Primary Outcome
The GRA evaluates the patients' perceptions of overall improvement in symptoms on a 7-point scale (markedly worse, moderately worse, mildly worse, unchanged, slightly improved, moderately improved, markedly improved).
Conditions Studied
Interventions
- DEVICE BTL Emsella Chair
- DEVICE Sham BTL Emsella Chair
Study Locations (1)
Michigan
- Corewell Health William Beaumont University Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2021-11-22 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT04873037 shows while recruiting
NCT04873037 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 46 other Overactive Bladder trials with a reported enrollment target (19% lower).
The record links to 4 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which BTL Emsella Chair is the first listed.
NCT04873037 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04873037 about?
NCT04873037 is a clinical study titled "BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder". The purpose of this clinical trial is to compare the Emsella Chair therapy to Sham and to determine whether electromagnetic technology is effective in the treatment of overactive bladder (OAB). Currently there are no other studies utilizing the Emsella Chair for the treatment of OAB. Eligible subjec...
What is the current status of trial NCT04873037?
This trial is currently recruiting. It is a NA study. The enrollment target is 166 participants. The study started on 2021-11-22. Estimated completion is 2028-12.
What conditions does trial NCT04873037 study?
This clinical trial studies the following conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Frequency, Urinary Urgency.
What interventions are being tested in trial NCT04873037?
The interventions under investigation include: BTL Emsella Chair (DEVICE), Sham BTL Emsella Chair (DEVICE).
Who is sponsoring clinical trial NCT04873037?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873037 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04873037's enrollment target sits among peer trials
166 17th of 46 higher than 30 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Percutaneous Nerve Evaluation Trial Time
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
RECRUITING · NA
-
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI